Roth MKM lowered the firm’s price target on CervoMed (CRVO) to $4 from $45 and keeps a Buy rating on the shares. The company has reported negative top-line results from the Phase 2b RewinD-LB – dementia with Lewy bodies – study of neflamapimod in pure DLB patients, raising questions about the program’s viability, the analyst tells investors in a research note. A potential reason for failure could be the drug’s inability to achieve the desired plasma concentration – a proxy for efficacy – and CervoMed is pausing Phase 3 preparations, originally scheduled to begin in the second half of FY25, the firm added.

Pick the best stocks and maximize your portfolio:

• Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!

• Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on CRVO:

• CervoMed price target lowered to $12 from $65 at Canaccord

• CervoMed downgraded to Underweight from Overweight at Morgan Stanley

• CervoMed downgraded to Neutral from Buy at Chardan

• CervoMed downgraded to Hold from Buy at Brookline

• CervoMed downgraded to Hold from Buy at JonesResearch